An­oth­er con­va­les­cent plas­ma tri­al for Covid-19 goes bust, but some ex­perts are still hold­ing out hope

A large, ran­dom­ized, place­bo-con­trolled tri­al found that the ad­min­is­tra­tion of Covid-19 con­va­les­cent plas­ma to high-risk out­pa­tients did not pre­vent the pro­gres­sion of Covid-19, ac­cord­ing to re­sults pub­lished Wednes­day in the New Eng­land Jour­nal of Med­i­cine.

The re­sult is an­oth­er blow to con­va­les­cent plas­ma, which has proven to be safe but has failed to show signs of ef­fi­ca­cy in some large RCTs, in­clud­ing a UK tri­al pub­lished in The Lancet in May, which found that high-titer con­va­les­cent plas­ma did not im­prove sur­vival or oth­er pre­spec­i­fied clin­i­cal out­comes in those hos­pi­tal­ized with Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER